Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.77 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.77 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.77 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.41 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | THPO | P40225 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL8152756 | 1.00 | OR51E2 (0.77) | OR51E2GLRA1SLC6A9GABRR1ACHE | |
| Glycine SCHEMBL6937710 | 0.96 | GLRA1 (0.71) | OR51E2GLRA1SLC6A9GABRR1ACHE | |
| Aminomethylamide SCHEMBL5699051 | 0.88 | — | — | |
| Glycine SCHEMBL29248317 | 0.88 | OR51E2 (0.83) | OR51E2GLRA1SLC6A9GABRR1ACHE | |
| Glycine SCHEMBL13739339 | 0.88 | — | — | |
| Glycine SCHEMBL30677914 | 0.88 | OR51E2 (0.83) | OR51E2GLRA1SLC6A9GABRR1ACHE | |
| Glycine SCHEMBL996872 | 0.88 | — | — | |
| Glycine SCHEMBL6163 | 0.88 | — | — | |
| Glycine SCHEMBL391027 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1ACHE | |
| Glycine SCHEMBL391786 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | claimed |
| EP-2598161-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | Amylin Pharmaceuticals, LLC (US) | 2013-06-05 | — | — | EP | claimed |
| WO-2012015975-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| EP-1206273-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2002-05-22 | — | — | EP | claimed |
| WO-2001010456-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | claimed |
| CN-114805481-B | Short peptide and slow release preparation with long-acting analgesic or/and long-acting local anesthetic effect by taking short peptide as carrier material | 四川大学华西医院 | 2023-06-23 | — | — | CN | disclosed |
| CN-113049579-A | Method and reagent for detecting lactose content | 上海蓝园生物工程有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| EP-1246638-B2 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA | AMYLIN PHARMACEUTICALS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2598161-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | Amylin Pharmaceuticals, LLC (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015975-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| CN-1777414-A | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2006-05-24 | — | — | CN | disclosed |
| US-20050037958-A1 | Inotropic and diuretic effects of GLP-1 and GLP-1 agonists | AMYLIN PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1246638-B1 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA | AMYLIN PHARMACEUTICALS INC (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1206273-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001010456-A2 | PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2001-02-15 | — | — | WO | disclosed |
| US-6117887-A | ANTIPROLIFERATIVE AGENTS | CV THERAPEUTICS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6040182-A | COATING PLASMA TREATED PLASTIC SURFACE WITH SOLUTION OF PROTEIN OR POLYPEPTIDE AT CONCENTRATION OF 1 NANOGRAM TO 2000 NANOGRAM PER MILLILITER IN A BUFFER, INCUBATING SOLUTION, WASHING TO REMOVE UNBOUND MATERIAL, AND DRYING; IMMUNOASSAYS | BECTON DICKINSON AND COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| US-5834487-A | ADMINISTERING DIPEPTIDE-SUBSTITUTED METHOXYINDANONES AS ENZYME INHIBITORS FOR TREATMENT OF CELL PROLIFERATION DISORDERS | CV THERAPEUTICS (US) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | GLP1R, GIPR, GCGR | OR51E2 965/4885GLRA1 128/4885SLC6A9 3862/4885 |
| US-20050037958-A1 | Inotropic and diuretic effects of GLP-1 and GLP-1 agonists | GLP1R, REN, NPPA | OR51E2 3726/4885GLRA1 1464/4885SLC6A9 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.